Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akoya BioSciences, Inc. - Common Stock (NQ:AKYA)

1.130 -0.100 (-8.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Akoya BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Looking Into Akoya Biosciences's Return On Capital Employed
Via Benzinga
Akoya Reports Record Revenue in the Fourth Quarter of 2022 and Provides Full Year 2023 Revenue Guidance
From Akoya Biosciences, Inc.
Via GlobeNewswire
A Preview Of Akoya Biosciences's Earnings
Via Benzinga
Akoya Biosciences Announces Appointment of Jennifer Kamocsay as General Counsel
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya to Report Fourth Quarter and Full Year 2022 Financial Results on March 6th, 2023 and Participate at Two Upcoming Investor Conferences
From Akoya Biosciences, Inc.
Via GlobeNewswire
Stephen Initiates This Spatial Biology Player Citing Strong Competitive Position
Via Benzinga
Akoya Biosciences: Q2 Earnings Insights
  Akoya Biosciences (NASDAQ:AKYA) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Akoya Biosciences to Present First-of-its-Kind Spatial Multiomics Dataset at 2023 AGBT General Meeting
Simultaneous detection of proteins and RNA markers across 23 different tissue samples demonstrate robust and scalable capabilities of company’s multiomics solution 
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2022
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya to Participate at 41st Annual J.P. Morgan Healthcare Conference
From Akoya Biosciences, Inc.
Via GlobeNewswire
Where Akoya Biosciences Stands With Analysts
Akoya Biosciences (NASDAQ:AKYA) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications
From Agilent Technologies Inc.
Via Business Wire
Akoya Biosciences Showcases Latest Spatial Biology Innovations at Virtual Spatial Day
From Akoya Biosciences, Inc.
Via GlobeNewswire
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday. 
Via Benzinga
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from the Centers for Medicare & Medicaid Services for the ProSense breast... 
Via Benzinga
Perrigo, Tripadvisor, Lyft, And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining more than 400 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Akoya Reports Record Revenue with 40% YoY Growth in the Third Quarter and Raises Full Year 2022 Revenue Guidance
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya Biosciences Launches PhenoCode Signature Panels to Accelerate Development of Predictive Biomarkers for Cancer Immunotherapy
From Akoya Biosciences, Inc.
Via GlobeNewswire
Preview: Akoya Biosciences's Earnings
Akoya Biosciences (NASDAQ:AKYA) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Akoya... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022
Upgrades 
Via Benzinga
Akoya to Participate at Three Upcoming Investor Conferences
From Akoya Biosciences, Inc.
Via GlobeNewswire
Akoya to Report Third Quarter 2022 Financial Results on November 7th, 2022
From Akoya Biosciences, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2022
Upgrades 
Via Benzinga
Akoya Biosciences's Return On Capital Employed Insights
Akoya Biosciences (NASDAQ:AKYA) brought in sales totaling $17.89 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 6.68%, resulting in a loss of $17.50 million. 
Via Benzinga
Why Bed Bath & Beyond Jumped Around 25%; Here Are 68 Biggest Movers From Yesterday
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
  
Via Benzinga
A Preview Of Akoya Biosciences's Earnings
Akoya Biosciences (NASDAQ:AKYA) is set to give its latest quarterly earnings report on Monday, 2022-08-08. Here's what investors need to know before the announcement. Analysts estimate that Akoya... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2022
Upgrades 
Via Benzinga
Akoya Biosciences Earnings Preview
Akoya Biosciences (NASDAQ:AKYA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Akoya... 
Via Benzinga
Earnings Scheduled For March 14, 2022
Companies Reporting Before The Bell • F45 Training Holdings (NYSE:FXLV) is projected to report earnings for its fourth quarter. • The One Group Hospitality (... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.